

# Philip K-T Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2336931/publications.pdf>

Version: 2024-02-01

181  
papers

7,511  
citations

61984

43  
h-index

58581

82  
g-index

190  
all docs

190  
docs citations

190  
times ranked

5093  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors and prognostic significance of persistent fluid overload: A longitudinal study in Chinese peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2023, 43, 252-262.	2.3	4
2	Adipose expression of miR-130b and miR-17-5p with wasting, cardiovascular event and mortality in advanced chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1935-1943.	0.7	8
3	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. <i>Patient Education and Counseling</i> , 2022, 105, 243-245.	2.2	2
4	Risk of peritonitis after gastroscopy in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2022, 42, 162-170.	2.3	4
5	Clinical course of peritoneal dialysis-related peritonitis due to non-tuberculosis mycobacterium " A single centre experience spanning 20 years. <i>Peritoneal Dialysis International</i> , 2022, 42, 204-211.	2.3	5
6	Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations. <i>Peritoneal Dialysis International</i> , 2022, 42, 8-24.	2.3	33
7	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	6.1	10
8	Stability and compatibility of antibiotics in peritoneal dialysis solutions. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1071-1078.	2.9	7
9	Patient-centred approaches for the management of unpleasant symptoms in kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 185-198.	9.6	60
10	Recent advances in novel diagnostic testing for peritoneal dialysis-related peritonitis. <i>Kidney Research and Clinical Practice</i> , 2022, , .	2.2	5
11	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. <i>Peritoneal Dialysis International</i> , 2022, 42, 110-153.	2.3	209
12	The Clinical Utility of the Neutrophil-to-Lymphocyte Ratio as a Discriminatory Test among Bacterial, Mycobacterium Tuberculosis, and Nontuberculous Mycobacterium Peritoneal Dialysis-Related Peritonitis. <i>Kidney360</i> , 2022, 3, 1031-1038.	2.1	4
13	Peritoneal dialysis first policy in <sc>Hong Kong</sc> for 35%years: Global impact. <i>Nephrology</i> , 2022, 27, 787-794.	1.6	14
14	Adipose and serum zinc alpha-2-glycoprotein (ZAG) expressions predict longitudinal change of adiposity, wasting and predict survival in dialysis patients. <i>Scientific Reports</i> , 2022, 12, .	3.3	4
15	Icodextrin in Peritoneal Dialysis: Implications on Clinical Practice and Survival Outcome. <i>Kidney360</i> , 2022, 3, 793-795.	2.1	0
16	Excessive risk and poor outcome of hospital-acquired peritoneal dialysis-related peritonitis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2107-2115.	2.9	3
17	Polymerase chain reaction/electrospray ionization" mass spectrometry (PCR/ESI-MS) is not suitable for rapid bacterial identification in peritoneal dialysis effluent. <i>Peritoneal Dialysis International</i> , 2021, 41, 96-100.	2.3	3
18	Kidney Health for Everyone Everywhere " From Prevention to Detection and Equitable Access to Care. <i>Blood Purification</i> , 2021, 50, 1-8.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. <i>Kidney International</i> , 2021, 99, 278-284.	5.2	36
20	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. <i>Indian Journal of Nephrology</i> , 2021, 31, 83.	0.5	0
21	Living Well with Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. <i>Nephron</i> , 2021, 145, 205-211.	1.8	3
22	Living Well with Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. <i>American Journal of Nephrology</i> , 2021, 52, 1-7.	3.1	3
23	Extended antibiotic therapy for the prevention of relapsing and recurrent peritonitis in peritoneal dialysis patients: a randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 991-997.	2.9	9
24	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e11098.	1.5	1
25	Living Well With Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. <i>Canadian Journal of Kidney Health and Disease</i> , 2021, 8, 205435812199527.	1.1	3
26	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. <i>Nephrology</i> , 2021, 26, 211-216.	1.6	0
27	Living Well With Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. <i>American Journal of Hypertension</i> , 2021, 34, 220-225.	2.0	3
28	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. <i>Nephrology (Saint-Petersburg)</i> , 2021, 25, 9-17.	0.4	0
29	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. <i>Internal Medicine Journal</i> , 2021, 51, 163-168.	0.8	0
30	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. <i>Journal of Renal Care</i> , 2021, 47, 3-8.	1.2	1
31	Living well with kidney disease by patient and care partner empowerment: kidney health for everyone everywhere. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 476-481.	2.9	0
32	Living Well With Kidney Disease by Patient and Care Partner Empowerment: Kidney Health for Everyone Everywhere. <i>Kidney International Reports</i> , 2021, 6, 553-556.	0.8	0
33	Living Well with Kidney Disease by patient and care-partner empowerment: Kidney Health for Everyone Everywhere. <i>Journal of Nephrology</i> , 2021, 34, 381-388.	2.0	2
34	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. <i>Nefrologia</i> , 2021, 41, 95-101.	0.4	2
35	Living well with kidney disease by patient and care partner empowerment: kidney health for everyone everywhere. <i>Transplant International</i> , 2021, 34, 391-397.	1.6	5
36	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 567-573.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Living Well With Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. <i>Kidney Medicine</i> , 2021, 3, 153-158.	2.0	1
38	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. <i>Nefrologia</i> , 2021, 41, 95-101.	0.4	2
39	Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 142-149.	0.9	1
40	World Kidney Day 2021: Living Well With Kidney Disease by Patient and Care Partner Empowermentâ€”Kidney Health for Everyone Everywhere. <i>American Journal of Kidney Diseases</i> , 2021, 77, 474-477.	1.9	4
41	Living Well With Kidney Disease by Patient and Carepartner Empowerment: Kidney Health for Everyone Everywhere. , 2021, 31, 233-238.		3
42	Progression in Physical Frailty in Peritoneal Dialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 342-351.	2.0	10
43	Living Well with Kidney Disease by Patient and Care-Partner Empowerment: Kidney Health for Everyone Everywhere. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021, 7, 1-7.	2.5	2
44	Depression in dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 600-612.	2.0	19
45	Impact of frailty and its inter-relationship with lean tissue wasting and malnutrition on kidney transplant waitlist candidacy and delisting. <i>Clinical Nutrition</i> , 2021, 40, 5620-5629.	5.0	11
46	Kidney microRNA-21 Expression and Kidney Function in IgA Nephropathy. <i>Kidney Medicine</i> , 2021, 3, 76-82.e1.	2.0	4
47	Living well with kidney disease by patient and care partner empowerment: kidney health for everyone everywhere. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 197-201.	0.7	1
48	Tackling Dialysis Burden around the World: A Global Challenge. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021, 7, 167-175.	2.5	17
49	Living Well With Kidney Disease by Patient and Care Partner Empowerment: Kidney Health for Everyone Everywhere. , 2021, 31, 554-559.		3
50	Living well with kidney disease by patient and care-partner empowerment: Kidney health for everyone everywhere. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2021, 32, 289.	0.3	0
51	Living Well with Kidney Disease by Patient and Care- Partner Empowerment: Kidney Health for Everyone Everywhere. <i>Iranian Journal of Kidney Diseases</i> , 2021, 1, 74-81.	0.1	0
52	Depression does not predict clinical outcome of Chinese peritoneal Dialysis patients after adjusting for the degree of frailty. <i>BMC Nephrology</i> , 2020, 21, 329.	1.8	9
53	Foreign Perspective on Achieving a Successful Peritoneal Dialysis-First Program. <i>Kidney360</i> , 2020, 1, 680-684.	2.1	8
54	Kidney Health for Everyone Everywhere â€” From Prevention to Detection and Equitable Access to Care. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020, 6, 136-143.	2.5	2

#	ARTICLE	IF	CITATIONS
55	Kidney Health for Everyone Everywhere â€œ From Prevention to Detection and Equitable Access to Care. American Journal of Nephrology, 2020, 51, 255-262.	3.1	2
56	Kidney Health for Everyone Everywhereâ€™From Prevention to Detection and Equitable Access to Care. Kidney International Reports, 2020, 5, 245-251.	0.8	1
57	Kidney Health for Everyone, Everywhereâ€™from prevention to detection and equitable access to care. Nephrology Dialysis Transplantation, 2020, 35, 367-374.	0.7	3
58	Kidney health for everyone everywhere - from prevention to detection and equitable access to care. Archivos Argentinos De Pediatr�a, 2020, 118, e148.	0.2	1
59	Kidney Health for Everyone Everywhere: From Prevention to Detection and Equitable Access to Care. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812091056.	1.1	3
60	Kidney Health for Everyone Everywhere: From Prevention to Detection and Equitable Access to Care. American Journal of Hypertension, 2020, 33, 282-289.	2.0	5
61	Kidney Health for Everyone Everywhere â€œ From Prevention to Detection and Equitable Access to Care. Nephron, 2020, 144, 162-169.	1.8	0
62	Reprint of: Kidney health for everyone everywhereâ€™from prevention to detection and equitable access to care. Nephrologie Et Therapeutique, 2020, 16, 211-216.	0.5	0
63	Kidney Health for Everyone Everywhere â€œ From prevention to detection and equitable access to care. Nefrologia, 2020, 40, 133-141.	0.4	1
64	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney International Reports, 2020, 5, 1129-1138.	0.8	14
65	Kidney health for everyone everywhereâ€™from prevention to detection and equitable access to care. Pediatric Nephrology, 2020, 35, 1801-1810.	1.7	4
66	Kidney health for everyone everywhereâ€™From prevention to detection and equitable access to care. Nephrology, 2020, 25, 195-201.	1.6	0
67	Helper-assisted continuous ambulatory peritoneal dialysis: Does the choice of helper matter?. Peritoneal Dialysis International, 2020, 40, 34-40.	2.3	13
68	Kidney Health for Everyone Everywhereâ€™From Prevention to Detection and Equitable Access to Care. Kidney Medicine, 2020, 2, 5-11.	2.0	2
69	Kidney Health for Everyone Everywhere â€œ From prevention to detection and equitable access to care. Nefrologia, 2020, 40, 133-141.	0.4	5
70	Kidney Health for Everyone Everywhereâ€™From Prevention to Detection and Equitable Access to Care. Journal of Renal Care, 2020, 46, 4-12.	1.2	8
71	Kidney health for everyone everywhereâ€™from prevention to detection and equitable access to care. Kidney International, 2020, 97, 226-232.	5.2	80
72	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Diseases, 2020, 75, 404-412.	1.9	92

#	ARTICLE	IF	CITATIONS
73	Strategies to prevent kidney disease and its progression. <i>Nature Reviews Nephrology</i> , 2020, 16, 129-130.	9.6	54
74	Kidney health for everyone everywhere: from prevention to detection and equitable access to care. <i>Journal of Nephrology</i> , 2020, 33, 201-210.	2.0	5
75	Longitudinal Changes of NF- $\kappa$ B Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients. <i>Scientific Reports</i> , 2020, 10, 6440.	3.3	8
76	Lessons of the month 3: Duodenal perforation after polystyrene sulfonate. <i>Clinical Medicine</i> , 2020, 20, 107-109.	1.9	10
77	Kidney health for everyone everywhere - From prevention to detection and equitable access to care. <i>Indian Journal of Nephrology</i> , 2020, 30, 63.	0.5	1
78	Kidney health for everyone everywhere - from prevention to detection and equitable access to care. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2020, 31, 298.	0.3	0
79	Kidney health for everyone everywhere “ from prevention to detection and equitable access to care. <i>Brazilian Journal of Medical and Biological Research</i> , 2020, 53, e9614.	1.5	6
80	Kidney Health for Everyone Everywhere, from Prevention to Detection and Equitable Access to Care. <i>Iranian Journal of Kidney Diseases</i> , 2020, 14, 69-80.	0.1	1
81	Metabolomic Changes of Human Proximal Tubular Cell Line in High Glucose Environment. <i>Scientific Reports</i> , 2019, 9, 16617.	3.3	14
82	GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1735-1745.	6.1	163
83	Relationship between Plasma Endocan Level and Clinical Outcome of Chinese Peritoneal Dialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 1259-1270.	2.0	18
84	Peritoneal Dialysis“Associated Peritonitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1100-1105.	4.5	80
85	Clinical practice guidelines for the provision of renal service in Hong Kong: Peritoneal Dialysis. <i>Nephrology</i> , 2019, 24, 27-40.	1.6	4
86	Clinical practice guidelines for the provision of renal service in Hong Kong: Accreditation of Renal Unit. <i>Nephrology</i> , 2019, 24, 130-132.	1.6	1
87	Urinary miRNA profile for the diagnosis of IgA nephropathy. <i>BMC Nephrology</i> , 2019, 20, 77.	1.8	26
88	Peritoneal protein clearance predicts mortality in peritoneal dialysis patients. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 551-560.	1.6	20
89	Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1601-1608.	6.1	34
90	Urinary mitochondrial DNA level is an indicator of intra-renal mitochondrial depletion and renal scarring in diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 784-788.	0.7	49

#	ARTICLE	IF	CITATIONS
91	Urinary mitochondrial DNA level as a biomarker of tissue injury in non-diabetic chronic kidney diseases. BMC Nephrology, 2018, 19, 367.	1.8	18
92	Chronic kidney disease epidemic: How do we deal with it?. Nephrology, 2018, 23, 116-120.	1.6	67
93	Peritoneal inflammation and fibrosis in C&#x2264;reactive protein transgenic mice undergoing peritoneal dialysis solution treatment. Nephrology, 2017, 22, 125-132.	1.6	4
94	Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: A report of four cases and review of literature. Nephrology, 2017, 22, 316-321.	1.6	19
95	Inflammation and Peritoneal Dialysis. Seminars in Nephrology, 2017, 37, 54-65.	1.6	58
96	Therapeutic drug monitoring of once&#x2013;daily tacrolimus (Advagraf) in a gastrectomized kidney transplant recipient. Nephrology, 2017, 22, 184-184.	1.6	0
97	Current Challenges and Opportunities in PD. Seminars in Nephrology, 2017, 37, 2-9.	1.6	10
98	ISPD Catheter-Related Infection Recommendations: 2017 Update. Peritoneal Dialysis International, 2017, 37, 141-154.	2.3	239
99	Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. Clinica Chimica Acta, 2017, 464, 106-112.	1.1	11
100	Changes in the worldwide epidemiology of peritoneal dialysis. Nature Reviews Nephrology, 2017, 13, 90-103.	9.6	384
101	In Memoriam of Henry Tenckhoff. Artificial Organs, 2017, 41, 697-699.	1.9	2
102	Urinary Mitochondrial DNA Level as a Biomarker of Acute Kidney Injury Severity. Kidney Diseases (Basel,) Tj ETQq0 0,0 rgBT /Overlock 10	2.5	17
103	Addressing the burden of dialysis around the world: <scp>A</scp> summary of the roundtable discussion on dialysis economics at the <scp>F</scp>irst <scp>I</scp>nternational <scp>C</scp>ongress of <scp>C</scp>hinese <scp>N</scp>ephrologists 2015. Nephrology, 2017, 22, 3-8.	1.6	10
104	Global impact of nephropathies. Nephrology, 2017, 22, 9-13.	1.6	16
105	Relatives in silent kidney disease screening (<scp>RISKS</scp>) study: <scp>A C</scp>hinese cohort study. Nephrology, 2017, 22, 35-42.	1.6	25
106	Urinary sediment mRNA level of extracellular matrix molecules in adult nephrotic syndrome. Clinica Chimica Acta, 2016, 456, 157-162.	1.1	7
107	Depression in dialysis patients. Nephrology, 2016, 21, 639-646.	1.6	104
108	Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis. CKJ: Clinical Kidney Journal, 2016, 9, 616-623.	2.9	14

#	ARTICLE	IF	CITATIONS
109	Dialysate bacterial endotoxin as a prognostic indicator of peritoneal dialysis related peritonitis. <i>Nephrology</i> , 2016, 21, 1069-1072.	1.6	9
110	Peritonitis before Peritoneal Dialysis Training: Analysis of Causative Organisms, Clinical Outcomes, Risk Factors, and Long-Term Consequences. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1219-1226.	4.5	15
111	ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. <i>Peritoneal Dialysis International</i> , 2016, 36, 481-508.	2.3	745
112	Treatment of hepatitis C virus infection in patients with CKD. <i>Nature Reviews Nephrology</i> , 2016, 12, 5-6.	9.6	4
113	Peritoneal Dialysis in Asia. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 147-156.	2.5	36
114	Urinary mRNA levels of ELR $\alpha$ -negative CXC chemokine ligand and extracellular matrix in diabetic nephropathy. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 699-706.	4.0	17
115	Predictors of Residual Renal Function Decline in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2015, 35, 180-188.	2.3	65
116	Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 829.	2.0	4
117	Sustainability of the Peritoneal Dialysis-First Policy in Hong Kong. <i>Blood Purification</i> , 2015, 40, 320-325.	1.8	40
118	Circulating Bacterial-Derived DNA Fragment Level Is a Strong Predictor of Cardiovascular Disease in Peritoneal Dialysis Patients. <i>PLoS ONE</i> , 2015, 10, e0125162.	2.5	31
119	Intrarenal and Urinary Th9 and Th22 Cytokine Gene Expression in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2015, 42, 1150-1155.	2.0	14
120	Questioning the effect of $\beta$ -blockers on vascular stiffness. <i>Nature Reviews Nephrology</i> , 2015, 11, 447-448.	9.6	1
121	Long-term Outcome of Biopsy-Proven Minimal Change Nephropathy in Chinese Adults. <i>American Journal of Kidney Diseases</i> , 2015, 65, 710-718.	1.9	35
122	Bioimpedance Spectroscopy for the Detection of Fluid Overload in Chinese Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2014, 34, 409-416.	2.3	60
123	Randomized controlled study of icodextrin on the treatment of peritoneal dialysis patients during acute peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1438-1443.	0.7	24
124	Prevalence of complications among Chinese diabetic patients in urban primary care clinics: a cross-sectional study. <i>BMC Family Practice</i> , 2014, 15, 8.	2.9	35
125	Peritoneal dialysis related peritonitis caused by <i>Gordonia</i> species: Report of four cases and literature review. <i>Nephrology</i> , 2014, 19, 379-383.	1.6	17
126	Clinical manifestation of macrolide antibiotic toxicity in CKD and dialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 507-512.	2.9	26



#	ARTICLE	IF	CITATIONS
127	Antibiotic therapy during CRRTâ€”getting the dose just right. <i>Nature Reviews Nephrology</i> , 2014, 10, 486-488.	9.6	2
128	MicroRNAs in IgA nephropathy. <i>Nature Reviews Nephrology</i> , 2014, 10, 249-256.	9.6	71
129	Peritoneal Dialysisâ€”First Policy Made Successful: Perspectives and Actions. <i>American Journal of Kidney Diseases</i> , 2013, 62, 993-1005.	1.9	105
130	Treatment of Early Immunoglobulin A Nephropathy by Angiotensin-converting Enzyme Inhibitor. <i>American Journal of Medicine</i> , 2013, 126, 162-168.	1.5	24
131	Bacteria-Derived DNA Fragment in Peritoneal Dialysis Effluent as a Predictor of Relapsing Peritonitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1935-1941.	4.5	31
132	Campylobacter Peritonitis Complicating Peritoneal Dialysis: A Review of 12 Consecutive Cases. <i>Peritoneal Dialysis International</i> , 2013, 33, 189-194.	2.3	4
133	Acute kidney injuryâ€”global health alert. <i>Nature Reviews Nephrology</i> , 2013, 9, 133-135.	9.6	9
134	Infectious complications in dialysisâ€”epidemiology and outcomes. <i>Nature Reviews Nephrology</i> , 2012, 8, 77-88.	9.6	69
135	Cross sectional survey on the concerns and anxiety of patients waiting for organ transplants. <i>Nephrology</i> , 2012, 17, 514-518.	1.6	18
136	Increasing home based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. <i>Nephrology</i> , 2011, 16, 53-56.	1.6	20
137	Asian Chronic Kidney Disease (CKD) Best Practice Recommendations - Positional Statements for Early Detection of CKD from Asian Forum for CKD Initiatives (AFCKDI). <i>Nephrology</i> , 2011, 16, no-no.	1.6	50
138	Increasing homeâ€”based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. <i>Hemodialysis International</i> , 2011, 15, 10-14.	0.9	11
139	Repeat Peritonitis in Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 827-833.	4.5	30
140	Elevated Levels of miR-146a and miR-155 in Kidney Biopsy and Urine from Patients with IgA Nephropathy. <i>Disease Markers</i> , 2011, 30, 171-179.	1.3	109
141	Expression of MicroRNAs in the Urinary Sediment of Patients with IgA Nephropathy. <i>Disease Markers</i> , 2010, 28, 79-86.	1.3	93
142	Effect of Membrane Permeability on Inflammation and Arterial Stiffness. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 652-658.	4.5	23
143	Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. <i>Peritoneal Dialysis International</i> , 2010, 30, 393-423.	2.3	770
144	The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 205-212.	2.9	6

#	ARTICLE	IF	CITATIONS
145	Recurrent and Relapsing Peritonitis: Causative Organisms and Response to Treatment. American Journal of Kidney Diseases, 2009, 54, 702-710.	1.9	62
146	Peritoneal Dialysis Patient Selection: Characteristics for Success. Advances in Chronic Kidney Disease, 2009, 16, 160-168.	1.4	26
147	Treatment of metabolic syndrome in peritoneal dialysis patients. Peritoneal Dialysis International, 2009, 29 Suppl 2, S149-52.	2.3	15
148	Success of the peritoneal dialysis programme in Hong Kong. Nephrology Dialysis Transplantation, 2008, 23, 1475-1478.	0.7	100
149	Metabolic syndrome in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2008, 1, 206-214.	2.9	10
150	Coagulase Negative Staphylococcal Peritonitis in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 91-97.	4.5	57
151	Staphylococcus aureus Peritonitis Complicates Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 245-251.	4.5	94
152	Continuous Ambulatory Peritoneal Dialysis Peritonitis: Broth Inoculation Culture versus Water Lysis Method. Nephron Clinical Practice, 2007, 105, c121-c125.	2.3	23
153	Development of the "Peritoneal Dialysis First" Model in Hong Kong. Peritoneal Dialysis International, 2007, 27, 53-55.	2.3	74
154	Increased Utilization of Peritoneal Dialysis to Cope with Mounting Demand for Renal Replacement Therapy—Perspectives from Asian Countries. Peritoneal Dialysis International, 2007, 27, 59-61.	2.3	25
155	Continuous Ambulatory Peritoneal Dialysis is Better than Automated Peritoneal Dialysis as First-Line Treatment in Renal Replacement Therapy. Peritoneal Dialysis International, 2007, 27, 153-157.	2.3	24
156	Maximizing the success of peritoneal dialysis in high transporters. Peritoneal Dialysis International, 2007, 27 Suppl 2, S148-52.	2.3	4
157	Continuous ambulatory peritoneal dialysis is better than automated peritoneal dialysis as first-line treatment in renal replacement therapy. Peritoneal Dialysis International, 2007, 27 Suppl 2, S153-7.	2.3	3
158	Good patient and technique survival in elderly patients on continuous ambulatory peritoneal dialysis. Peritoneal Dialysis International, 2007, 27 Suppl 2, S196-201.	2.3	25
159	Increased utilization of peritoneal dialysis to cope with mounting demand for renal replacement therapy—perspectives from Asian countries. Peritoneal Dialysis International, 2007, 27 Suppl 2, S59-61.	2.3	7
160	Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): A Double-Blind, Randomized, Placebo-Controlled Study. American Journal of Kidney Diseases, 2006, 47, 751-760.	1.9	177
161	Predictive Value of Dialysate Cell Counts in Peritonitis Complicating Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 768-773.	4.5	78
162	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney International, 2005, 67, S2-S7.	5.2	55

#	ARTICLE	IF	CITATIONS
163	Prevalence of silent kidney disease in Hong Kong: The Screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program. <i>Kidney International</i> , 2005, 67, S36-S40.	5.2	44
164	Hypokalemia in Chinese Peritoneal Dialysis Patients: Prevalence and Prognostic Implication. <i>American Journal of Kidney Diseases</i> , 2005, 46, 128-135.	1.9	84
165	Peritoneal Albumin Excretion is a Strong Predictor of Cardiovascular Events in Peritoneal Dialysis Patients: A Prospective Cohort Study. <i>Peritoneal Dialysis International</i> , 2005, 25, 445-452.	2.3	46
166	Transforming Growth Factor- $\beta$ 1 Gene Polymorphism in Renal Transplant Recipients. <i>Renal Failure</i> , 2005, 27, 671-675.	2.1	21
167	The clinical course of peritoneal dialysis-related peritonitis caused by <i>Corynebacterium</i> species. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2793-2796.	0.7	27
168	The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2005, 25 Suppl 3, S80-3.	2.3	12
169	Cefazolin plus Ceftazidime versus Imipenem / Cilastatin Monotherapy for Treatment of Capd Peritonitis – a Randomized Controlled Trial. <i>Peritoneal Dialysis International</i> , 2004, 24, 440-446.	2.3	37
170	The clinical course of culture-negative peritonitis complicating peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2003, 42, 567-574.	1.9	73
171	Effects of an Angiotensin-Converting Enzyme Inhibitor on Residual Renal Function in Patients Receiving Peritoneal Dialysis. <i>Annals of Internal Medicine</i> , 2003, 139, 105.	3.9	252
172	Is There a Survival Advantage in Asian Peritoneal Dialysis Patients?. <i>International Journal of Artificial Organs</i> , 2003, 26, 363-372.	1.4	12
173	Conservative management of polymicrobial peritonitis complicating peritoneal dialysis – a series of 140 consecutive cases. <i>American Journal of Medicine</i> , 2002, 113, 728-733.	1.5	56
174	Comparison of clinical outcome and ease of handling in two double-bag systems in continuous ambulatory peritoneal dialysis: A prospective, randomized, controlled, multicenter study. <i>American Journal of Kidney Diseases</i> , 2002, 40, 373-380.	1.9	70
175	Feasibility of Resuming Peritoneal Dialysis after Severe Peritonitis and Tenckhoff Catheter Removal. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1040-1045.	6.1	101
176	Clinical course of peritonitis due to <i>Pseudomonas</i> species complicating peritoneal dialysis: A review of 104 cases. <i>Kidney International</i> , 2001, 59, 2309-2315.	5.2	108
177	Independent Effects of Residual Renal Function and Dialysis Adequacy on Actual Dietary Protein, Calorie, and Other Nutrient Intake in Patients on Continuous Ambulatory Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2450-2457.	6.1	122
178	Impact of Dialysis Adequacy on the Mortality and Morbidity of Anuric Chinese Patients Receiving Continuous Ambulatory Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 355-360.	6.1	93
179	Noncardiogenic Pulmonary Edema Associated with Triazolam. <i>Journal of Toxicology: Clinical Toxicology</i> , 1995, 33, 185-187.	1.5	2
180	Salt and Water Balance in Peritoneal Dialysis. , 0, , 488-499.		1

#	ARTICLE	IF	CITATIONS
181	Reply to "Stability and compatibility of antibiotics in PD solutions - Call for including antibiotics for drug-resistant infections". CKJ: Clinical Kidney Journal, 0, , .	2.9	0